Overview
| 别名 | Kinesin-like protein KIF21A; Kinesin-like protein KIF2; Renal carcinoma antigen NY-REN-62 |
| 基因名 | KIF21A |
| UniProt ID | Q7Z4S6 |
| 反应种属 | Human |
| 应用 | WB,IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG2a |
| 克隆号 | 2K2-B7-D4 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 187 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:1000; IHC-1:100-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Kinesin family member 21A (KIF21A) is a plus end–directed, processive motor protein that regulates axon guidance and cortical microtubule dynamics by binding microtubules and hydrolyzing ATP. Highly expressed in neurons, it interacts with KANK1/2 to inhibit microtubule growth at the cell cortex, thereby shaping axon extension and pathfinding. The protein's activity is tightly controlled by an intramolecular autoinhibition mechanism. Pathogenic heterozygous missense mutations in KIF21A, which typically disrupt this autoinhibition and lead to constitutive motor activity, are the primary cause of autosomal dominant congenital fibrosis of the extraocular muscles type 1 (CFEOM1). This condition is characterized by restrictive ophthalmoplegia and ptosis resulting from abnormal cranial motor axon development. |
检测原理